Difference between revisions of "Team:CGU Taiwan/Safety"
| Line 331: | Line 331: | ||
<div class="mid" style="top:155px;"> | <div class="mid" style="top:155px;"> | ||
<h1 style="font-size:40px;color:#140731;text-decoration:none;position:absolute;left:220px;top:10px;margin:20px;">Safety</h1> | <h1 style="font-size:40px;color:#140731;text-decoration:none;position:absolute;left:220px;top:10px;margin:20px;">Safety</h1> | ||
| + | |||
| + | <div style"position:absolute;width:100%;height:800px;top:40px;"> | ||
| + | <h4 style="font-size:23px;color:#140731;text-decoration:none;position:absolute;left:270px;top:30px;margin:20px;">(1)Short introduction of our project</h4> | ||
| + | <p style="color:black;text-decoration:none;font-size:18px;position:absolute;left:300px;top:60px;margin-right:220px;margin-left:50px;margin-top:30px;text-align:justify;">Transgenic Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to the APCs for T cells and humoral response. Based on this concept, we established a new model system to generate antigen-specific inactive Leishmania adjuvant (Leijuvant).</p> | ||
| + | </div> | ||
| + | |||
| + | <div style"position:absolute;width:100%;height:800px;top:150px;"> | ||
| + | <h4 style="font-size:23px;color:#140731;text-decoration:none;position:absolute;left:270px;top:30px;margin:20px;">(2)What organisms do we use? </h4> | ||
| + | <p style="color:black;text-decoration:none;font-size:18px;position:absolute;left:300px;top:60px;margin-right:220px;margin-left:50px;margin-top:30px;text-align:justify;">Leishmania, DC2.4, E.coli(DH5α, BL21), C57BL/6 mice</p> | ||
| + | </div> | ||
| + | |||
| + | <div style"position:absolute;width:100%;height:800px;top:350px;"> | ||
| + | <h4 style="font-size:23px;color:#140731;text-decoration:none;position:absolute;left:270px;top:30px;margin:20px;">(3)Which parts do we use? </h4> | ||
| + | <p style="color:black;text-decoration:none;font-size:18px;position:absolute;left:300px;top:60px;margin-right:220px;margin-left:50px;margin-top:30px;text-align:justify;">Full length of HA and OVA: We used full length sequence of hemagglutinin (HA) of H1N1 and Ovalbumin as our testing antigen that is expressed in Leishmania.<br><br>5’UTR, 3’UTR, 2.3kb intron: the sequence is originally from Leishmania genome. Act as promotor, terminator, and expression modulating part in our device. </p> | ||
| + | </div> | ||
Revision as of 09:11, 19 October 2016
Leijuvant
Safety
(1)Short introduction of our project
Transgenic Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to the APCs for T cells and humoral response. Based on this concept, we established a new model system to generate antigen-specific inactive Leishmania adjuvant (Leijuvant).
(2)What organisms do we use?
Leishmania, DC2.4, E.coli(DH5α, BL21), C57BL/6 mice
(3)Which parts do we use?
Full length of HA and OVA: We used full length sequence of hemagglutinin (HA) of H1N1 and Ovalbumin as our testing antigen that is expressed in Leishmania.
5’UTR, 3’UTR, 2.3kb intron: the sequence is originally from Leishmania genome. Act as promotor, terminator, and expression modulating part in our device.
